Rhode Island 2022 Regular Session

Rhode Island House Bill H7587

Introduced
2/18/22  
Refer
2/18/22  
Report Pass
6/17/22  
Engrossed
6/21/22  
Engrossed
6/23/22  

Caption

Accident And Sickness Insurance Policies -- Biomarker Testing Coverage

Impact

If passed, the bill will specifically alter statutes regarding health insurance policies by compelling insurers to provide comprehensive coverage for biomarker testing. This regulation is expected to limit disruptions in care, such as multiple biopsies for diagnosis, and ensure that testing is conducted in a manner that adheres to established clinical guidelines. As a result, patients may experience better health outcomes, as they will receive information critical to their treatment management.

Summary

House Bill 7587 aims to mandate health insurers in Rhode Island to cover biomarker testing under accident and sickness insurance policies from January 1, 2024. The legislation specifically defines biomarker testing as the analysis of patient biospecimens to identify characteristics that can guide clinical decisions, such as gene mutations and protein expressions. This requirement seeks to enhance the diagnostic and treatment processes for patients by ensuring that they have access to crucial health information that influences their care.

Sentiment

The sentiment surrounding House Bill 7587 appears to be generally positive among healthcare advocates, who argue that the coverage for biomarker testing is essential for optimizing patient care. Supporters emphasize the importance of having modern medical resources accessible to patients, ensuring they receive precise treatments. However, there may be concerns regarding the financial implications for health insurers and potential increases in policy costs, leading to a more cautious reception from some fiscal policymakers.

Contention

A notable point of contention may arise from how biomarker testing is defined and the parameters surrounding what constitutes 'clinical utility.' Lawmakers will need to carefully assess the implications of including such testing in standard insurance policies since different types of biomarker tests vary in their scientific backing and clinical applications. Discussions may focus on balancing the need for comprehensive coverage while managing the costs and practicality for health insurance providers.

Companion Bills

No companion bills found.

Similar Bills

RI S2201

Accident And Sickness Insurance Policies -- Biomarker Testing Coverage

FL H0805

Health Insurance Coverage for Biomarker Testing

TN HB0484

AN ACT to amend Tennessee Code Annotated, Title 56 and Title 71, relative to coverage of biomarker testing.

TN SB0435

AN ACT to amend Tennessee Code Annotated, Title 56 and Title 71, relative to coverage of biomarker testing.

NM HB73

Biomarker Testing Insurance Requirements

ME LD1577

An Act to Require Health Insurance Coverage for Biomarker Testing

CA SB636

Workers’ compensation: utilization review.

DE SB24

An Act To Amend Title 14 Of The Delaware Code Relating To The Seizure Safe Schools Act.